In several Workshop discussions EMAV members developed key elements of future manufacturing standards for autogenous vaccines - in execution of regulation (EU) 2019/6. These findings were implemented in a draft of dedicated GMP rules for autogenous vaccines by the EMAV Scientific Working Group, an expert team from the EMAV membership experienced in regularory procedures, quality assurance and manufacturing of vaccines.
For the definition of basic requirements for the target-oriented use of autogenous vaccine by Vet professionals in different species in an European harmonized market EMAV Board has established another expert team focussed on the appropriate usage of autogenous vaccines under field conditions. As members of the „EMAV Practice Advisory Group“ were appointed Maarten De Gussem (Poulpharm/Belgium), Matthias Todte (AvicarePlus/Germany), Klaus Teich (AniCon/Germany), Maarten van den Berg (Brabants Veterinair Laboratorium/The Netherlands), Bart Engelen (c/o RIPAC-LABOR/Germany) and Jean de Foucauld (Ceva Biovac/France). Maarten de Gussem, member of the EMAV Board, will coordinate the activities of the Practice Advisory Group yet.
Gerfried Zeller, Managing Director of EMAV, pointed out that he’s very pleased for the support of this new expert team in the development of valid common positions for the use of Autogenous vaccines in cattle, swine, poultry, fish and companion animals in practice now. As well as for the new advisory competence for the EMAV membership in all questions of prophylactic use of vaccines for animal health protection.